Based in Shizuoka, Sunsho Pharmaceutical is one of the largest contract manufacturers in Japan of soft capsules, seamless capsules and other dosage forms for pharmaceutical and H&N use. The company is focused on producing absolute quality products and applying cutting edge contract manufacturing technology to create cutting edge formulations and capsules.
CJP SP Holding, LPacquired a 100% stake in Sunsho Pharmaceutical in August 2014 through Carlyle’s third buyout fund in Japan, Carlyle Japan Partners III, after recognizing the strong growth potential of the company as a subcontractor on a H&N market in constant growth in Japan. Carlyle also saw the potential for value creation with Sunsho Pharmaceutical and in the H&N market in Japan by leveraging the knowledge of her local team, the strengths of her global platform and her deep experience in the healthcare industries. and consumption.
Through the ownership of Carlyle, Sunsho Pharmaceutical has strengthened its management structure and governance, initiated the launch of a new factory and research and development center to improve production capacities, diversified its portfolio of activities to meet new customers and has significantly increased its global revenues by strengthening and expanding its overseas business. Carlyle has also worked closely with the Sunsho Pharmaceutical leadership team to help drive innovation and co-create new value-added products and solutions with customers.
Carlyle will transfer full ownership to Towa Pharmaceutical to support Sunsho Pharmaceutical’s next phase of growth.
Carlyle has made 31 investments in Japan since entering the market in 2000 and this will be the 20th release to date. Carlyle has a well-established history of investing in the healthcare industry, both in Japan and around the world, investing more than US $ 14.7 billion in equity in more than 80 transactions in the global healthcare industry. healthcare as of September 30, 2021. Investments in healthcare in Japan include Qualicaps Co., Ltd. and Solasto Corporation.
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital in three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $ 293 billion in assets under management as of September 30, 2021, Carlyle’s goal is to invest wisely and create value on behalf of its investors, the companies in its portfolio and the communities in which we live. and let’s invest. Carlyle employs more than 1,800 people in 26 offices on five continents.
More information is available at www.carlyle.com. Follow Carlyle on Twitter @OneCarlyle.
About Sunsho Pharmaceutical
Sunsho Pharmaceutical is a company which plans, develops and carries out under contract the manufacture of H&N and pharmaceutical products, being a major player in the H&N market in Japan. Sunsho Pharmaceutical has complete factories in Shizuoka and offers contract manufacturing and packaging of soft capsules, seamless capsules and other dosage forms. In addition to manufacturing capacity and technology, Sunsho Pharmaceutical has first-class capability in R&D technology, sales force and quality control system. The company has various certificates including cGMP, GMP and HACCP. The company was founded in 1993 and currently employs 690 people.
For more information, visit the company’s website at: https://www.sunsho.co.jp/en/
+852 9023 1157
Jochen Legewie / Minako Otani
+81 3 5156 0185 / +81 3 5156 0190